Company intelligence / Profile preview

Nuvamid

Lausanne/Épalinges, Vaud, Switzerlandlinkedin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead molecule NUV01 is currently being evaluated in three Phase 2 trials. NUV01 is considered extremely safe. A Phase 1 clinical trial (NCT06133478) was completed, which was a double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of NUV001 in healthy adult participants.

Therapeutic areas: Hematology
Modalities: Small moleculesNucleotide-Based Therapies
Industry: Biotech

Drug pipeline

2 assets

NUV001

1 more asset in the full pipeline.

Request access →

Partnerships

Lausanne University (Switzerland)EFSINSERMCNRS (France)Buck Institute (USA)

Beyond the preview

Go deeper on Nuvamid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvamid.

Explore the full profile